stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) EPS (diluted)
Maravai LifeSciences Holdings, Inc.'s EPS (diluted) for fiscal 2025 was −$0.90, compared with −$1.05 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.43. Over the past ten years it has ranged from −$1.05 (fiscal 2024) to $2.36 (fiscal 2020); the current reading is higher than 38% of that period. Maravai LifeSciences Holdings, Inc. ranks 117th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.90 | — |
| FY2024 | −$1.05 | — |
| FY2023 | −$0.90 | — |
| FY2022 | $1.67 | 7.05% |
| FY2021 | $1.56 | (33.90%) |
| FY2020 | $2.36 | — |
| FY2019 | −$0.02 | — |
| FY2018 | −$0.07 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.09 | — |
| Jun 2026 | −$0.08 | — |
| Mar 2026 | −$0.02 | — |
| Dec 2025 | −$0.24 | — |
| 24 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $3.02 |
| TRVI Trevi Therapeutics, Inc. compare | −$0.34 |
| MRVI Maravai LifeSciences Holdings, Inc. | −$0.43 |
| MESO Mesoblast Limited compare | −$1.12 |
| VIR Vir Biotechnology, Inc. compare | −$1.26 |
| SRPT Sarepta Therapeutics, Inc. compare | −$1.37 |
| MAZE Maze Therapeutics, Inc. compare | −$2.52 |
| REPL Replimune Group, Inc. compare | −$2.79 |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$5.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item